FDA reviewers voice concern about side effects of belatacept

02/25/2010 | Los Angeles Times (tiered subscription model)

Bristol-Myers Squibb's kidney transplant drug belatacept extended survival better than older treatments, FDA reviewers said, but it also appeared to cause a higher rate of severe kidney rejection and neurological disease. A panel of experts is scheduled to evaluate the drug's safety and efficacy next week.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN